Antibodies

16 Jun 2008 Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP
15 Jun 2008 New data reveals Actemra is the first and only biologic drug to show superiority over current standard of care in rheumatoid arthritis
15 Jun 2008 Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis
15 Jun 2008 New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
15 Jun 2008 Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
15 Jun 2008 HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis with Combination Treatment Resulted in Cost Savings From Improved Work Productivity
12 Jun 2008 Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
12 Jun 2008 ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
11 Jun 2008 Ofatumumab in subcutaneous study in rheumatoid arthritis
11 Jun 2008 Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
10 Jun 2008 Symphogen Enters into strategic collaboration with Genentech for antibody thera-peutics
09 Jun 2008 Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
09 Jun 2008 XOMA 052 Demonstrates Anti-Inflammatory Effect in Arthritis Animal Studies; Data Presented At FOCIS
08 Jun 2008 WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE(R) (CA9-SCAN)
05 Jun 2008 Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
05 Jun 2008 Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
05 Jun 2008 Merck Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
05 Jun 2008 Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
04 Jun 2008 ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
04 Jun 2008 Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma
04 Jun 2008 BioInvent and ThromboGenics report positive Phase I results for anti-PlGF cancer therapeutic TB-403
04 Jun 2008 Bradmer Receives FDA Approval to Proceed with Phase III Clinical Trial
03 Jun 2008 Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma
03 Jun 2008 Trubion Announces Presentation of Positive TRU-016 Data at ASCO
03 Jun 2008 New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing’s Sarcoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top